What were the most common adverse reactions reported in clinical trials of vestronidase alfa?

In four trials involving 23 patients, the most common adverse reactions to vestronidase alfa were rash, urticaria and infusion-site extravasation (17.4% each), anaphylactoid reaction (13%), and infusion-site swelling, pruritus and diarrhoea (8.7% each); most were mild to moderate.